Dose-dense chemotherapy in advanced ovarian cancer

被引：12
作者：
Bookman, Michael A. [1 ]
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA
来源：
LANCET | 2009年 / 374卷 / 9698期
关键词：
PHASE-III TRIAL; GYNECOLOGIC-ONCOLOGY-GROUP; RANDOMIZED-TRIAL; WEEKLY PACLITAXEL; BREAST-CANCER; INTERGROUP; PLATINUM; CARBOPLATIN; CISPLATIN; INFUSION;
D O I：
10.1016/S0140-6736(09)61305-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1303 / 1305
页数：3
相关论文
共 14 条
[1]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[2]   Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].
Bookman, Michael A. ;
Brady, Mark F. ;
McGuire, William P. ;
Harper, Peter G. ;
Alberts, David S. ;
Friedlander, Michael ;
Colombo, Nicoletta ;
Fowler, Jeffrey M. ;
Argenta, Peter A. ;
De Geest, Koen ;
Mutch, David G. ;
Burger, Robert A. ;
Swart, Ann Marie ;
Trimble, Edward L. ;
Accario-Winslow, Chrisann ;
Roth, Lawrence M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425
[3]   2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [J].
du Bois, A ;
Quinn, M ;
Thigpen, T ;
Vermorken, J ;
Avall-Lundqvist, E ;
Bookman, M ;
Bowtell, D ;
Brady, M ;
Casado, A ;
Cervantes, A ;
Eisenhauer, E ;
Friedlaender, M ;
Fujiwara, K ;
Grenman, S ;
Guastalla, JP ;
Harper, P ;
Hogberg, T ;
Kaye, S ;
Kitchener, H ;
Kristensen, G ;
Mannel, R ;
Meier, W ;
Miller, B ;
Neijt, JP ;
Oza, A ;
Ozols, R ;
Parmar, M ;
Pecorelli, S ;
Pfisterer, J ;
Poveda, A ;
Provencher, D ;
Pujade-Lauraine, E ;
Randall, M ;
Rochon, J ;
Rustin, G ;
Sagae, S ;
Stehman, F ;
Stuart, G ;
Trimble, E ;
Vasey, P ;
Vergote, I ;
Verheijen, R ;
Wagner, U .
ANNALS OF ONCOLOGY, 2005, 16 :7-12
[4]   EUROPEAN-CANADIAN RANDOMIZED TRIAL OF PACLITAXEL IN RELAPSED OVARIAN-CANCER - HIGH-DOSE VERSUS LOW-DOSE AND LONG VERSUS SHORT INFUSION [J].
EISENHAUER, EA ;
HUININK, WWT ;
SWENERTON, KD ;
GIANNI, L ;
MYLES, J ;
VANDERBURG, MEL ;
KERR, I ;
VERMORKEN, JB ;
BUSER, K ;
COLOMBO, N ;
BACON, M ;
SANTABARBARA, P ;
ONETTO, N ;
WINOGRAD, B ;
CANETTA, R .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2654-2666
[5]   Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia [J].
Guminski, AD ;
Harnett, PR ;
deFazio, A .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (03) :229-234
[6]   Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial [J].
Katsumata, Noriyuki ;
Yasuda, Makoto ;
Takahashi, Fumiaki ;
Isonishi, Seiji ;
Jobo, Toshiko ;
Aoki, Doisuke ;
Tsuda, Hiroshi ;
Sugiyama, Toru ;
Kodama, Shoji ;
Kimura, Eizo ;
Ochiai, Kazunori ;
Noda, Kiichiro .
LANCET, 2009, 374 (9698) :1331-1338
[7]   Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? [J].
Lau, D ;
Guo, LL ;
Gandara, D ;
Young, LJI ;
Xue, L .
ANTI-CANCER DRUGS, 2004, 15 (09) :871-875
[8]   Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study [J].
Markman, Maurie ;
Blessing, John ;
Rubin, Stephen C. ;
Connor, Joseph ;
Hanjani, Parviz ;
Waggoner, Steven .
GYNECOLOGIC ONCOLOGY, 2006, 101 (03) :436-440
[9]   Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup study [J].
Omura, GA ;
Brady, MF ;
Look, KY ;
Averette, HE ;
Delmore, JE ;
Long, HJ ;
Wadler, S ;
Spiegel, G ;
Arbuck, SG .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2843-2848
[10]   Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840 [J].
Seidman, Andrew D. ;
Berry, Donald ;
Cirrincione, Constance ;
Harris, Lyndsay ;
Muss, Hyman ;
Marcom, P. Kelly ;
Gipson, Grandella ;
Burstein, Harold ;
Lake, Diana ;
Shapiro, Charles L. ;
Ungaro, Peter ;
Norton, Larry ;
Winer, Eric ;
Hudis, Clifford .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1642-1649
12